Thryv Therapeutics
PrivateLast Round
Series B
Nov 3, 2026
Total Funding Raised
$71.74M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Thryv Therapeutics operates in Healthcare & Life Sciences and is based in Montreal. Its latest recorded funding round was a Series B round in November 2026.
Thryv Therapeutics is a biotechnology company that develops precision medicine therapies for genetic arrhythmia syndromes, heart failure, and atrial fibrillation using selective SGK1 inhibitors.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Thryv Therapeutics Comparables
Compare Thryv Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| AnaCardio | 86% | |
| Cardurion Pharmaceuticals | 86% | |
| Acesion Pharma | 84% |
For institutional investors. Book with your work email.
Thryv Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Nov 3, 2026 | ||||
| Convertible Debt | Jun 6, 2023 | ||||
| Series A Extension | Jul 11, 2022 | ||||
| Series A | Aug 10, 2021 | ||||
| Seed | Jan 8, 2020 | ||||
Seed | Nov 6, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Thryv Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Amzak Health | Series A |
| Investissement Québec | Convertible Debt, Series B |
| CTI Life Sciences Fund | Series B |
| Amplitude Ventures | Series B, Series A |
| Investissement Québec | Series B, Convertible Debt |
| Fonds de solidarité FTQ | Series A, Series B, Seed |
| Alexandria Venture Investments | Series A, Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 3, 2026
$30M round led by InClin, Inc.
- Oct 5, 2026
Grew 18% QoQ, from 28 to 33 employees.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- receives_financingNov 3, 2026
On Nov 3rd '26, Thryv Therapeutics Inc. receives $30M Series B financing led by InClin, Inc., with continued support from existing investors, to advance THRV-1268 into the ASPIRE-HF Phase 2a heart failure study in California.
For institutional investors. Book with your work email.
Thryv Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Thryv Therapeutics's valuation, stock price, and market status.
Is Thryv Therapeutics a public or private company?
Thryv Therapeutics is a private company.
What is the current stock price of Thryv Therapeutics?
Thryv Therapeutics is a private company, so its shares have no public market price. Caplight tracks Thryv Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Thryv Therapeutics worth (valuation)?
Valuation information for Thryv Therapeutics is not publicly available.
Can I buy Thryv Therapeutics stock?
Thryv Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Thryv Therapeutics's last funding round?
Thryv Therapeutics's most recent funding round was Series B on November 3, 2026.
Who are the main investors in Thryv Therapeutics?
Key investors in Thryv Therapeutics include Amplitude Ventures, Investissement Québec, Fonds de solidarité FTQ.
Will Thryv Therapeutics IPO soon?
No public IPO plans have been announced for Thryv Therapeutics.
How can I track Thryv Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Thryv Therapeutics's shares on secondary markets.